Treatment of acute lymphoblastic leukemia : 30 years' experience at St. Jude Children's Research Hospital

Background Therapy for childhood lymphoblastic leukemia has evolved during the past three decades, but key questions about what are the least toxic, most effective forms of treatment remain unanswered because of the lack of comprehensive follow-up information. Methods To assess long-term outcome in the series of clinical trials conducted at St. Jude Hospital, we compared the results of treatment typical of four eras: exploratory combination chemotherapy (era 1, 1962 to 1966; 91 patients), regimens for the control of meningeal leukemia (era 2, 1967 to 1979; 825 patients), limited intensification of therapy (era 3, 1979 to 1983; 428 patients), and extended intensification of therapy (era 4, 1984 to 1988; 358 patients). (“Intensification” refers to strategies of systemic chemotherapy that are more aggressive than conventional ones.) The major end points were survival and event-free survival; we also calculated the relative risk of treatment failure and the rate of relapse or death after treatment ended (post...

[1]  M. Relling,et al.  Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. , 2009, NCI monographs : a publication of the National Cancer Institute.

[2]  L. Frankel,et al.  Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Frankel,et al.  Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Wei Chen,et al.  T-cell immunity to the joining region of p210BCR-ABL protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Schell,et al.  Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. , 1992, Blood.

[6]  F. Behm,et al.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. , 1991, The New England journal of medicine.

[7]  R. Gelber,et al.  Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). , 1991, Blood.

[8]  R. Gelber,et al.  Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[10]  M. Schell,et al.  Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Behm,et al.  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.

[12]  D. Campana,et al.  The immunologic detection of minimal residual disease in acute leukemia. , 1990, Blood.

[13]  H. Sather,et al.  INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES Early Conclusions of Study CCG-106 by the Childrens Cancer Study Group , 1988, The Lancet.

[14]  G. Rivera The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Mulhern,et al.  Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Look,et al.  Prognostic value of cellular DNA content in acute lymphoblastic leukemia of childhood. , 1987, The New England journal of medicine.

[17]  A. Look,et al.  Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[19]  S L George,et al.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.

[20]  Bleyer Wa,et al.  Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. , 1985 .

[21]  S L George,et al.  Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. , 1984, Cancer research.

[22]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[23]  S. George,et al.  Second cessation of therapy in childhood lymphocytic leukemia. , 1979, Blood.

[24]  R. Aur,et al.  Childhood acute lymphocytic leukemia. Study VIII , 1978, Cancer.

[25]  R. Aur,et al.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1977, The New England journal of medicine.

[26]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[27]  J. Simone FACTORS THAT INFLUENCE HAEMATOLOGICAL REMISSION DURATION IN ACUTE LYMPHOCYTIC LEUKAEMIA , 1976, British journal of haematology.

[28]  R. Aur,et al.  A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia , 1972, Cancer.

[29]  R. Aur,et al.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. , 1971, Blood.

[30]  R. Aur,et al.  Drug dosage and remission duration in childhood lymphocytic leukemia , 1971, Cancer.

[31]  D. Pinkel Therapy of acute lymphoid leukemia in children. , 1992, Leukemia.

[32]  R. Mulhern,et al.  Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Pui,et al.  Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. , 1988, Medical and pediatric oncology.

[34]  A. Bleyer,et al.  Analysis of prognostic factors in acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.

[35]  B. Camitta,et al.  Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. , 1980, Medical and pediatric oncology.